Dror Ben-Asher, Chairman
Mr. Ben-Asher has extensive managerial and transactional expertise, He was previously with ProSeed Capital, a European corporate finance boutique. Mr. Ben-Asher is a graduate of the University of Oxford (M.Jur.) and completed LL.M. studies at Harvard University. At Harvard, Mr. Ben-Asher was also a Fulbright Scholar focusing on the pharmaceutical industry and markets, an Olin Fellow for Law, Economics and Business, and an Economics Teaching Fellow at Harvard’s Economics Department. Mr. Ben-Asher received an LL.B. with distinction (First Class Honours) from the University of Leicester.
Dan Suesskind, Director
Mr. Suesskind, who served 31 years as CFO of Teva Pharmaceutical Industries (NYSE: TEVA) until 2008, had played a pivotal role in the strategic activities of the Israeli generic pharmaceuticals giant, including the acquisition of more than 30 companies. During that period, Teva grew from a small Israeli company with a market cap of $37 million, into a leading global company with a market cap exceeding $34 billion in 2008. Mr. Suesskind is a member of Teva’s board of directors. Mr. Suesskind also serves as a board member at Migdal Group (one of Israel’s leading insurance and finance groups), Gefen Biomed Investment (TASE: GEFEN), NESS Technologies (NASDAQ: NSTC), Syneron Medical (NASDAQ: ELOS) and the Jerusalem Foundation. He holds a BA in economics and political science from the Hebrew University and an MBA from the University of Massachusetts. Mr. Suesskind is a member of the Israeli Forum of Chief Financial Officers and was awarded the “Life Time Achievement Award” from that forum in 2007.
Ori Shilo, Director
Mr. Shilo has extensive financial and transactional expertise. He was previously with ProSeed Capital, the Israeli Antitrust Authority and Delloite & Touche Consulting. Mr. Shilo received an MBA (Finance) from Ben Gurion University and a B.A. in Business Administration (Magna Cum Laude) from the College of Management, Tel Aviv.
Eric Swenden, Director
Mr. Swenden had a long and successful career in finance and company management. He held various senior positions in companies including Vandemoortele Food Group and General Bank (Fortis) and Lifeline Scientific (current).
Kenneth Reed MD, Director
Dr. Reed is an experienced physician and director. He is currently with Kenneth Reed M.D. P.C. (Dermatologist) and Minerva Biotechnologies. Dr. Reed was also a Clinical Investigator for companies including Amgen, Astellas and Centocor (J&J). He is a graduate of Harvard Medical School (residency in dermatology), Thomas Jefferson University Hospital (medical internship), College of Medicine and Dentistry of New Jersey (M.D.) and Brown University (B.A.).
Shmuel Cabilly PhD, Director
Mr. Cabilly is a highly regarded scientist and an experienced director. He was previously with several companies including Ethrog Biotech (Co-Founder and Chief Scientist) which was sold to Invitrogen. He graduated from the Hebrew University (Ph.D., Immunology), and was a Post-Doctoral fellow at the City of Hope Research Institute heading a joint City of Hope/Genentech project where he developed a new technology for recombinant antibody production.
Alicia Rotbard, Director
Ms. Rotbard is an experienced professional director and corporate governance expert, with extensive international business experience. Ms. Rotbard has been actively serving in the past 13 years as a board member of several public and private companies, including, among others, Israel Discount Bank, Hadera Paper (AMEX:AIP, TASE: HAP), Kamada (TASE:CMDA), Pointer (NASDAQ: PNTR), B.G.I Investments (TASE: BGI) and AIG Israel. Ms. Rotbard is the founder and former CEO of Doors Information Systems, Inc., and former president and CEO of Quality Computers Ltd. Ms. Rotbard served also as Deputy General Manager of the Tel- Aviv Stock Exchange. She holds a B.Sc. in Mathematics and Physics from the Hebrew University of Jerusalem.
Ofer Tsimchi, Director
Mr. Tsimchi has many years of business experience in various executive positions. Mr. Tsimchi is the co-founder and manager of Danbar Group and serves as the Chairman of Polysack (TASE: PLSK). Mr. Tsimchi served as a board member of several companies including, among others, Tefron (TASE:TFRN) and Kapro Industries Ltd. (present). Mr. Tsimchi holds a B.Sc. in Economics and Agriculture from the Hebrew University of Jerusalem.